三生制药：分拆蔓迪国际于港交所主板独立上市

Core Viewpoint - The company, 3SBio Inc. (01530.HK), announced plans to spin off its subsidiary, Mandiant, for an independent listing on the Hong Kong Stock Exchange, subject to various approvals and considerations [1] Group 1 - The proposed spin-off of Mandiant is contingent upon approvals from relevant authorities, final decisions from the boards of both the company and Mandiant, as well as market and other factors [1] - The completion of the spin-off is not guaranteed, indicating potential uncertainties surrounding the process [1] - Shareholders and other investors are advised to exercise caution when trading the company's securities during this period [1]